Nightstar Therapeutics to Participate in Multiple Conferences in November
31 October 2017 - 7:05AM
YASTEST
LEXINGTON, Mass. and LONDON, Oct. 30,
2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE),
a clinical-stage gene therapy company developing treatments for
rare inherited retinal diseases, today announced that the company
will participate in the following industry and investor conferences
in November:
- Ophthalmology Innovation Summit on
Thursday, November 9, 2017 at 8:54 a.m. ET in New Orleans
- Jefferies London Healthcare
Conference on Thursday, November 16, 2017 at 2:40 p.m. GMT in
London
- Barclays Gene Editing & Gene
Therapy Summit on Thursday, November 30, 2017 at 11 a.m. ET in New
York City
The presentation at the Jefferies
London Healthcare Conference will be webcast live and available for
replay at ir.nightstartx.com.
About Nightstar
Nightstar is a leading clinical-stage
gene therapy company focused on developing and commercializing
novel one-time treatments for patients suffering from rare
inherited retinal diseases that would otherwise progress to
blindness. Nightstar's lead product candidate, NSR-REP1, is being
developed as a treatment for patients with choroideremia, a rare,
degenerative, genetic retinal disorder that has no current
treatments and affects approximately one in every 50,000 people.
Positive results from a Phase 1/2 trial of NSR-REP1 were published
in The Lancet in 2014 and in The New England Journal
of Medicine in 2016. Nightstar plans to commence a Phase 3
registrational trial of NSR-REP1 for choroideremia at sites in the
United States, Europe and Canada in the first half of 2018.
Nightstar's second product candidate, NSR-RPGR, is currently being
evaluated in a Phase 1/2 clinical trial for the treatment of
patients with X-linked retinitis pigmentosa, an inherited X-linked
recessive retinal disease that affects approximately one in every
40,000 people.
For more information about Nightstar
or its clinical trials, please visit www.nightstartx.com.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to: statements about our plans to develop and commercialize
our product candidates, our planned clinical trials for NSR-REP1
and NSR-RPGR, the clinical utility of our product candidates, the
prevalence of patient populations for our targeted indications, and
the utility of prior preclinical and clinical data in determining
future clinical results. These forward-looking statements are based
on management's current expectations of future events and are
subject to a number of involve substantial known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements, including the risks and uncertainties
set forth in the "Risk Factors" section of our prospectus filed
pursuant to Rule 424(b)(4) under the U.S. Securities Act of 1933,
as amended, on September 28, 2017, and subsequent reports that we
file with the U.S. Securities and Exchange Commission. We may not
actually achieve the plans, intentions or expectations disclosed in
our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we make.
The forward-looking statements in this presentation represent our
views as of the date of this presentation. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking
statements at some point in the future, we have no current
intention of doing so except to the extent required by applicable
law. You should, therefore, not rely on these forward-looking
statements as representing our views as of any date subsequent to
the date of this presentation.
Contact:
Senthil Sundaram, Chief Financial
Officer
investors@nightstartx.com
Alicia Davis, THRUST IR
910-620-3302
alicia@thrustir.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Nightstar Therapeutics via Globenewswire
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jul 2023 to Jul 2024